Following the FDA approval of vonoprazan in the treatment of erosive esophagitis, Dr Colin Howden discussed important information about the new therapy. In the wake of the recent FDA approval of ...

The FDA has approved vonoprazan as a therapy for erosive gastroesophageal reflux disease. The phase 3 PHALCON-EE study found vonoprazan was more effective in reducing stomach acid compared to other ...

Please provide your email address to receive an email when new articles are posted on . On-demand vonoprazan improved heartburn symptoms in nonerosive reflux disease within 1 hour of treatment. High ...

In a span of three days, Phathom Pharmaceuticals has scored two green lights from the FDA for its first-in-class heartburn drug Voquezna (vonoprazan). The first came Monday when the regulator signed ...

Please provide your email address to receive an email when new articles are posted on . On-demand vonoprazan relieved heartburn within 3 hours in up to 70% of patients vs. placebo. An exploratory ...

Vonoprazan (Voquezna) was noninferior to lansoprazole (Prevacid) for healing patients with erosive esophagitis, and was superior for maintaining healing, a randomized trial showed. In a modified ...

Share on Pinterest The FDA has approved vonoprazan (Voquezna), a new daily treatment for heartburn associated with GERD in adults. andreswd/Getty Images The FDA approved vonoprazan (Voquezna) as a ...

FLORHAM PARK, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...

The randomized, double-blind, multicenter PHALCON-NERD-301 study included 776 adults with symptomatic NERD. Vonoprazan was associated with a significantly greater percentage of 24-hour heartburn free ...

FLORHAM PARK, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...

The US Food and Drug Administration (FDA) has approved vonoprazan 10 mg and 20 mg tablets (Voquezna, Phathom Pharmaceuticals) for the healing and maintenance of healing of all grades of erosive ...

The FDA approved vonoprazan (Voquezna) as a daily treatment for heartburn associated with non-erosive gastroesophageal reflux disease (GERD) in adults. GERD is a condition in which acidic stomach ...